HPK1 inhibitor NDI-101150 shows safety and antitumour activity in ccRCC
HPK1 inhibitor NDI-101150 shows safety and antitumour activity in ccRCC
Catequentinib improves PFS vs placebo in advanced or metastatic leiomyosarcoma
Ropeginterferon Alfa-2b shows superior efficacy over anagrelide in essential thrombocythaemia
New MOAs in prostate cancer treatment - what’s next?
Abemaciclib potential therapeutic option for Kaposi sarcoma
ASCO 2025: Latest in EGFR positive NSCLC
Nivolumab/ipilimumab followed by BRAF/MEK inhibitors preferred sequence for BRAF-positive advanced melanoma
Sasanlimab BCG combo improves outcomes in high-risk NMIBC
Neoadjuvant PD-1 blockade enables organ preservation in early dMMR tumours without surgery
Vepdegestrant could extend PFS for some ESR1-mutated advanced breast cancers
Olaparib boosts chemotherapy’s impact on BRCA-mutated breast cancer
WRN inhibitor shows promise in patients with MSI and/or dMMR advanced solid tumours